Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.33 USD | -2.00% | -37.94% | -18.91% |
12:55pm | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
08/05 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.91% | 244M | |
+11.29% | 226B | |
+8.97% | 188B | |
+13.29% | 137B | |
+26.13% | 108B | |
+0.34% | 63.19B | |
+11.53% | 52.26B | |
+5.62% | 51B | |
+6.31% | 43.89B | |
+4.80% | 38.07B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16